# A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

> **NCT07052253** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** TT-00420 (tinengotinib)
- **DRUG:** AK104
- **DRUG:** AK112

## Key facts

- **NCT ID:** NCT07052253
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2027-05-10
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052253, "A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07052253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*